Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2mutation identified in a cell-free DNA or tumor tissue genotyping assay.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Emory University, Northwestern Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Vanderbilt University, Weill Cornell Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Albert Einstein College of Medicine, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, Los Angeles, UCLA Health, UCLA Jonsson Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W4399349506